FDA Clampdown On Excessive Anti-Aging Claims May Lighten Up In 2017
This article was originally published in The Rose Sheet
FDA issued close to 30 warning letters to cosmetics firms in 2016 for unapproved drug claims as part of “a project for reviewing product labels and websites for drug claims related to anti-aging.” That initiative may be winding down, if it hasn’t already, but the agency is playing its cards close to its vest going into the new year.
You may also be interested in...
The agency told Rose Sheet it’s unaware of any health concerns related to probiotic cosmetic use, but it’s currently reviewing product labeling and available literature on the subject. Companies should be aware that by current regulatory standards, probiotic-containing cosmetics may well be adulterated.
Statements about collagen production, maintaining cellular integrity, addressing age spots, even shrinking wrinkles and treating noncystic acne – all are viable structure/function claims for nutricosmetics, assuming there's evidence to back them up. The Rose Sheet discusses the growing opportunity with regulatory and legal experts and provides an overview of the market at present.
Healthy Habits reacts indignantly to FDA’s warning about testimonials for DermaTox products featured on its website, which the agency says identify the items as unapproved drugs. Aegeia Skin Care also receives a warning letter for structure/function and disease-treatment claims on its facial- and body-care products.